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■ CLINICAL COMMENTARY
Thin-prep Pap smears can make workup
of ASCUS easier for physician and patient
The management of ASCUS Pap smears has
often confused primary care doctors. This is
confounded by the fact that it is often a chal-
lenge to ensure that patients follow our recom-
mendations. How could we blame them—after
all, who wants to undergo 4 Pap smears
instead of 1? The advent of thin-prep Pap
smears, with reflex HPV testing on the same
specimen, has simplified our lives. By obtain-
ing routine thin-prep Pap smears and then
reflex HPV testing for only high-risk HPV
types, fewer Pap smears and colposcopic
exams are needed, without reducing the detec-
tion of HSIL. Best of all, fewer women are
overtreated or lost to follow-up.
John Hill, MD, University of Colorado Health Sciences
Center, Denver
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Are ARBs or ACE inhibitors
preferred for nephropathy 
in diabetes?
■ EVIDENCE-BASED ANSWER
Angiotensin receptor blockers (ARBs) have been
shown to reduce the progression of nephropathy
in several consistent studies. While ACE
inhibitors have not been as well studied for the
endpoint of nephropathy, patients with nephropa-
thy exhibit reduced mortality when treated with
an ACE inhibitor (strength of recommendation:
A, based on randomized controlled trials).
■ EVIDENCE SUMMARY
The RENAAL (Reduction of Endpoints in
NIDDM with the Angiotensin II Antagonist
Losartan) study1—a multicenter, randomized,
double-blind, placebo-controlled trial—followed
1513 patients with type 2 diabetes and nephropa-
thy over a mean of 3.4 years. Patients were 
randomized to receive losartan (Cozaar) or 
placebo, both taken in addition to conventional
anti-hypertensive therapy (but not including 
renin-angiotensin-aldosterone system antagonist
medications). The primary outcome was a compos-
ite of a doubling of serum creatinine, end-stage
renal disease, or death. The number needed to treat
(NNT) for the composite outcome was 34. The NNT
for a doubling of the serum creatinine was 25, and
for end-stage renal disease was 17.
The 2-year IRMA (Irbesartan Microalbumin-
uria) study,2 a multicenter, randomized, double-
blind, placebo-controlled trial, randomized 590
patients with type 2 diabetes, hypertension, and
persistent microalbuminuria to receive 150 or 300
mg of irbesartan (Avapro) or placebo. Additional
antihypertensive agents were allowed in each arm
with the exception of ACE inhibitors, ARBs, and
dihydropyridine calcium-channel blockers. The
primary outcome was the development of overt
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■ CLINICAL COMMENTARY
ARBs not yet shown to be as good as
ACE inhibitors at reducing mortality
The evidence is good that ARBs delay the
progression of type 2 diabetic nephropathy.
Although more studies have looked at ARBs
than ACE inhibitors in nephropathy from type
2 diabetes, ARBs have not been shown to be
as good as ACE inhibitors at reducing all-
cause mortality, the most important patient-
oriented outcome.
Brett H. Foreman, MD, M. Lee Chambliss, MD,
MPH, Moses Cone Health System, Greensboro, NC
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DRUG BRAND NAMES
Amlodipine • Norvasc
Amoxicillin • Amoxil, Biomox, Polymox, Trimox, Wymox
Azithromycin • Zithromax
Cefaclor • Ceclor
Cephalexin • Biocef, Keflex
Clarithromycin • Biaxin
Clindamycin • Cleocin, Dalacin
Irbesartan • Avapro
Losartan • Cozaar
Ramipril • Altace
Vancomycin • Vancocin
Warfarin • Coumadin
Xylometazoline • Otrivin
nephropathy defined by a urinary albumin excretion
rate >200 µg/min that is at least 30% higher than
the baseline rate. This trial showed that irbesar-
tan delayed progression to nephropathy inde-
pendent of its effect on blood pressure compared
with conventional therapy (NNT=16 at the 150-
mg dose and NNT=11 at the 300-mg dose).
A third double-blind, placebo-controlled
trial—IDNT (Irbesartan Diabetic Nephropathy
Trial3—randomized 1715 patients to irbesartan,
amlodipine (Norvasc), or placebo for a median
follow-up of 2.6 years. Each group could also
use other conventional antihypertensive thera-
py (but again excluding ACE inhibitors, ARBs,
and calcium-channel blockers). Irbesartan
reduced progression of nephropathy (defined by
doubling of the serum creatinine) and the onset
of end-stage renal disease more effectively than
amlodipine (NNT=12) or placebo (NNT=16).
Irbesartan did not decrease cardiovascular mor-
tality, nonfatal myocardial infarction, heart fail-
ure resulting in hospitalization, neurologic
deficit caused by a cerebrovascular event, or
above-ankle lower-limb amputation.
The mortality benefit with ARBs has not
been as consistent as that shown with ACE
inhibitors. Both classes of drugs conferred
reduced mortality as seen with ramipril in the
HOPE (Heart Outcomes Prevention Evaluation)
trial4 and losartan in the LIFE (Losartan
Intervention For Life) trial.5 However, a survival
benefit was not seen with irbesartan in the
RENAAL and IDNT trials.
■ RECOMMENDATION FROM OTHERS
The American Diabetes Association recom-
mends both ACE inhibitors and ARBs for the
treatment of early nephropathy in hypertension
to delay the progression of microalbuminuria to
macroalbuminuria and overt nephropathy.6
The mortality benefit with ARBs 
has not been as consistent 
as that shown with ACE inhibitors
